Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations

Core Insights - Cidara Therapeutics has completed target enrollment of 6,000 participants in its Phase 3 ANCHOR trial for CD388, a non-vaccine preventative for seasonal influenza, aimed at high-risk populations [1][2] - The trial will conduct an interim analysis in Q1 2026 to evaluate the need for additional enrollment during the Southern Hemisphere flu season [1][2] - CD388 is designed to be administered as a single 450-milligram subcutaneous dose and aims for potential BLA approval if the trial results are successful [2][4] Company Overview - Cidara Therapeutics utilizes its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) therapeutics, with CD388 being its lead candidate for influenza prevention [4] - The company is headquartered in San Diego, California, and has received Fast Track Designation from the FDA for CD388 [4] - Positive results from the Phase 2b NAVIGATE trial were announced in June 2025, leading to the initiation of the Phase 3 ANCHOR trial in September 2025 [4]